CelluTarget · Multifocal Motor Neuropathy · Clinical Trials
Phase 1
Recruiting
NCT05032196

WVE-003

Sponsored by Wave Life Sciences ↗
View on ClinicalTrials.gov ↗
Timeline
Study Dates
Start Date
September 2021
Est. Completion
December 2027
Enrollment Target
60 participants
Status
Recruiting
Study Design
Primary Endpoint
Safety, tolerability, pharmacokinetics, and allele-selective reduction of mutant huntingtin protein in CSF
Registry
ClinicalTrials.gov Record
Registry ID
NCT05032196
Direct Link
clinicaltrials.gov/NCT05032196 ↗
Related Treatment
Treatment Being Studied
WVE-003 →